Abstract:The WHO recommends dolutegravir as part of first-line antiretroviral therapy (ART) for persons living with HIV [1]. Consequently, pregnant women living with HIV (WLHIV) are increasingly receiving dolutegravir-based ART worldwide. Although some studies have reported on birth outcomes in this population [2], there are no data on fetal biometry in pregnant WLHIV receiving dolutegravir. We assessed the association of dolutegravir-based or efavirenz-based ART with fetal biometry, using a comparison group of HIV/ART-unexposed fetuses. We enrolled pregnant WLHIV and pregnant women without HIV between 16 and 36 weeks gestation in the Tshilo Dikotla cohort in Botswana from August 2016 to May 2019. WLHIV received tenofovir and emtricitabine and either dolutegravir (dolutegravir-based ART) or efavirenz (efavirenz-based ART) during pregnancy. Pregnancies with multiple gestations or ending in fetal demise were excluded. The study was approved by the Human Research and Development Committee in Botswana and the Institutional Review Boards at Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital of Chicago. Head circumference, biparietal diameter, abdominal circumference, and femoral length Z scores from a single ultrasound performed in the second trimester were calculated using INTERGROWTH-21st standards [3]. Linear regression models were fit to assess the association of in-utero HIV/ART exposure with each fetal biometric Z score. Of the 469 pregnant women enrolled, 182 received dolutegravir-based ART, 127 efavirenz-based ART, and 160 were without HIV. WLHIV on efavirenz-based ART were oldest, followed by those on dolutegravir-based ART and those without HIV (median age 32 vs. 28 vs. 24 years, respectively, P < 0.01), highest in parity (3 vs. 2 vs. 1, respectively, P < 0.01), and least likely to have completed tertiary education (7.9% vs. 14.3% vs. 33.1%, respectively, P < 0.01). Gestational age at ultrasound was higher in WLHIV than women without HIV (28 vs. 26 weeks, P < 0.01). Viral load and CD4 values were similar between WLHIV on dolutegravir-based vs. efavirenz-based ART (Table 1). Table 1 - Fetal biometry and neonatal anthropometric Z scores by in-utero HIV/antiretroviral therapy exposure status. In-utero exposure to HIV and TDF/FTC/DTG In-utero exposure to HIV and TDF/FTC/EFV HIV/ART-unexposed P value Fetuses n = 182 n = 127 n = 160 HC –0.4 (–1.0, 0.3) –0.5 (–1.1, 0.0) –0.3 (–0.9, 0.4) 0.060 BPD 0.1 (–0.6, 0.8) –0.0 (–0.7, 0.7) 0.1 (–0.6, 0.7) 0.464 AC 0.3 (–0.4–0.7) 0.5 (–0.2–1.0) 0.1 (–0.5–0.8) 0.172 FL 1.5 (0.7–2.0) 1.5 (0.8–2.1) 1.3 (0.5–2.1) 0.396 Estimated FW 0.6 (0.2–0.9) 0.7 (0.4–1.0) 0.5 (0.0–1.0) 0.347 Neonates n = 166 n = 144 n = 131 BW –0.2 (–0.9, 0.6) –0.1 (–0.9, 0.7) –0.1 (–0.8, 0.5) 0.575 BL 1.1 (0.0, 2.1) 1.2 (0.0, 2.0) 1.3 (–0.0, 2.4) 0.458 BHC –0.4 (–1.0, 0.3) –0.5 (–1.1, 0.0) –0.3 (–0.9, 0.4) 0.060 AC, abdominal circumference; ART, antiretroviral therapy; BHC, birth head circumference; BL, birth length; BPD, biparietal diameter; BW, birth weight; DTG, dolutegravir; FL, fetal length; FTC, emtricitabine; FW, fetal weight; HC, head circumference; TDF, tenofovir. In unadjusted analyses, overall, Z scores for all fetal biometry measurements did not differ significantly between groups (Table 1). Findings persisted after adjusting for maternal age, height, education level, parity and alcohol use in pregnancy. Birth anthropometrics were available for 94% of infants and were similar between groups. In this cohort in Botswana, there were no differences in fetal biometry between fetuses exposed to dolutegravir-based ART, those exposed to efavirenz-based ART, and those unexposed to HIV/ART. This is the first study to evaluate fetal biometric measurements in pregnant WLHIV receiving dolutegravir. Fetal ultrasound including fetal biometry is an important tool for measuring fetal well being, anomalies, and growth, allowing early detection and subsequent management of potential in-utero conditions which may place the fetus or mother at risk for poor outcomes at birth/delivery [4]. Though our study was limited by its single site study design, small sample size, and the lack of longitudinal ultrasonography, these results appear reassuring and support the continued use of dolutegravir-based regimens in pregnancy. Larger studies with serial ultrasonography are needed to validate these findings. Acknowledgements F.M.B. drafted the first version of the article. K.M.P. and J.J. conceptualized the study. S.S. performed the data analysis. F.M.B., K.M.P., S.S., J.M., G.M., L.M.Y., and J.J. reviewed the article, whereas K.M.P., L.M.Y., and J.J. gave substantive feedback on the final version. The study was funded by the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) (R01DK109881). Conflicts of interest The authors have no financial conflicts of interest to disclose.

Bictegravir Use During Pregnancy: A Multi-Center Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes

Safety of Anti-hepatitis B Virus Therapy During Pregnancy and Lactation

Effect of Prophylactic Antiviral Intervention on T Cell Immunity in Hepatitis B Virus-Infected Pregnant Women

Fetal Biometry Following In-Utero Exposure to Dolutegravir-Based or Efavirenz-Based Antiretroviral Therapy

Comparison of Antiretroviral Therapies in Pregnant Women Living With Human Immunodeficiency Virus and Hepatitis B Virus: A Randomized Controlled Trial

Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV

Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy

Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy

Comparative risk of adverse perinatal outcomes associated with classes of antiretroviral therapy in pregnant women living with HIV: systematic review and meta-analysis

The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B

Efficacy and safety of 2-drug regime dolutegravir/lamivudine in pregnancy and breastfeeding - clinical implications and perspectives

The impact of Option B+ policy on engagement in HIV care and viral suppression among pregnant women living with HIV in South Africa

Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants

The impact of pregnancy on anti-HIV activity of cervicovaginal secretions

Prospective Cohort Study on the Efficacy and Safety of Telbivudine Used Throughout Pregnancy in Blocking Mother-to-child Transmission of Hepatitis B Virus.

Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy

Safety and Efficacy of Telbivudine in Late Pregnancy to Prevent Mother‐to‐child Transmission of Hepatitis B Virus: A Multicenter Prospective Cohort Study

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study

Antiretroviral Therapy in Pregnancy: A 2023 Review of the Literature

Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum